Lytixar (LTX-109) / Lytix 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   15 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lytixar (LTX-109) / Lytix
NCT05889351 / 2022-001938-11: Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Completed
2a
27
Europe
Vehicle gel, 4 + 4 applications or 4 + 2 applications, LTX-109 3% gel, 4 + 4 applications, LTX-109 3% gel, 4 + 2 applications
Pharma Holdings AS, CTC Clinical Trial Consultants AB
Nasal Decolonization of Staphylococcus Aureus
10/22
10/22
2020-000042-34: Proof of concept-studie av LTX-109 som effektiv behandling mot hidrosadenitt (svettekjertelbetennelse)

Not yet recruiting
2
12
Europe
LTX-109
Hidradenitis suppurativa, Hurley stage I-III, Hidradenitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT04854928 / 2021-000455-39: Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

Recruiting
2
60
Europe
LTX-109 gel, 3%, Placebo gel
Pharma Holdings AS, CTC Clinical Trial Consultants AB
COVID-19
02/22
05/22
2022-001938-11: A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus

Not yet recruiting
2
27
Europe
LTX-109 Hydrogel 3% w/w, Gel
Pharma Holdings AS, Pharma Holdings AS
Eradication of Staphylococcus aureus from the nose., Bacterial eradication from the nose., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 

Download Options